Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions.

Sherr JL, Buckingham BA, Forlenza GP, Galderisi A, Ekhlaspour L, Wadwa RP, Carria L, Hsu L, Berget C, Peyser TA, Lee JB, O'Connor J, Dumais B, Huyett LM, Layne JE, Ly TT.

Diabetes Technol Ther. 2019 Oct 29. doi: 10.1089/dia.2019.0286. [Epub ahead of print]

PMID:
31596130
2.

A Technological Revolution: The Integration of New Treatments to Manage Type 1 Diabetes.

Galderisi A, Sherr JL.

Pediatr Ann. 2019 Aug 1;48(8):e311-e318. doi: 10.3928/19382359-20190725-03.

PMID:
31426099
3.

Pharmacologic treatment options for type 1 diabetes: what's new?

Nally LM, Sherr JL, Van Name MA, Patel AD, Tamborlane WV.

Expert Rev Clin Pharmacol. 2019 May;12(5):471-479. doi: 10.1080/17512433.2019.1597705. Review.

PMID:
30892094
4.

Connecting the Dots: Validation of Time in Range Metrics With Microvascular Outcomes.

Hirsch IB, Sherr JL, Hood KK.

Diabetes Care. 2019 Mar;42(3):345-348. doi: 10.2337/dci18-0040. No abstract available.

PMID:
30787056
5.

Reversal of Ketosis in Type 1 Diabetes Is Not Adversely Affected by SGLT2 Inhibitor Therapy.

Siebel S, Galderisi A, Patel NS, Carria LR, Tamborlane WV, Sherr JL.

Diabetes Technol Ther. 2019 Mar;21(3):101-104. doi: 10.1089/dia.2018.0356. Epub 2019 Jan 28.

PMID:
30688521
6.

Enlarging the loop: closed-loop insulin delivery for type 1 diabetes.

Galderisi A, Sherr JL.

Lancet. 2018 Oct 13;392(10155):1282-1284. doi: 10.1016/S0140-6736(18)32329-8. Epub 2018 Oct 3. No abstract available.

7.

Gender differences in diabetes self-care in adults with type 1 diabetes: Findings from the T1D Exchange clinic registry.

Shah VN, Wu M, Polsky S, Snell-Bergeon JK, Sherr JL, Cengiz E, DiMeglio LA, Pop-Busui R, Mizokami-Stout K, Foster NC, Beck RW; for T1D Exchange Clinic Registry.

J Diabetes Complications. 2018 Oct;32(10):961-965. doi: 10.1016/j.jdiacomp.2018.08.009. Epub 2018 Aug 10.

PMID:
30121205
8.

Accuracy of a Fourth-Generation Continuous Glucose Monitoring System in Children and Adolescents with Type 1 Diabetes.

Slover RH, Tryggestad JB, DiMeglio LA, Fox LA, Bode BW, Bailey TS, Brazg R, Christiansen MP, Sherr JL, Tsalikian E, Kaiserman KB, Sullivan A, Huang S, Shin J, Lee SW, Kaufman FR.

Diabetes Technol Ther. 2018 Sep;20(9):576-584. doi: 10.1089/dia.2018.0109. Epub 2018 Jul 31.

PMID:
30063162
9.

ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes technologies.

Sherr JL, Tauschmann M, Battelino T, de Bock M, Forlenza G, Roman R, Hood KK, Maahs DM.

Pediatr Diabetes. 2018 Oct;19 Suppl 27:302-325. doi: 10.1111/pedi.12731. No abstract available.

PMID:
30039513
10.

Closing the Loop on Managing Youth With Type 1 Diabetes: Children Are Not Just Small Adults.

Sherr JL.

Diabetes Care. 2018 Aug;41(8):1572-1578. doi: 10.2337/dci18-0003. Epub 2018 Jun 23. Review.

11.

Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: International comparison from the T1D Exchange and DPV Initiative.

DeSalvo DJ, Miller KM, Hermann JM, Maahs DM, Hofer SE, Clements MA, Lilienthal E, Sherr JL, Tauschmann M, Holl RW; T1D Exchange and DPV Registries.

Pediatr Diabetes. 2018 Nov;19(7):1271-1275. doi: 10.1111/pedi.12711. Epub 2018 Jul 1.

12.

Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System.

Messer LH, Forlenza GP, Sherr JL, Wadwa RP, Buckingham BA, Weinzimer SA, Maahs DM, Slover RH.

Diabetes Care. 2018 Apr;41(4):789-796. doi: 10.2337/dc17-1682. Epub 2018 Feb 14.

13.

Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study.

Patel NS, Van Name MA, Cengiz E, Carria LR, Weinzimer SA, Tamborlane WV, Sherr JL.

Diabetes Technol Ther. 2017 Nov;19(11):618-622. doi: 10.1089/dia.2017.0267. Epub 2017 Oct 25.

14.

Moving beyond subcutaneous insulin: the application of adjunctive therapies to the treatment of type 1 diabetes.

Ang KH, Sherr JL.

Expert Opin Drug Deliv. 2017 Sep;14(9):1113-1131. doi: 10.1080/17425247.2017.1360862. Epub 2017 Aug 3. Review.

PMID:
28774208
15.

The dawn of automated insulin delivery: A new clinical framework to conceptualize insulin administration.

Messer LH, Forlenza GP, Wadwa RP, Weinzimer SA, Sherr JL, Hood KK, Buckingham BA, Slover RH, Maahs DM.

Pediatr Diabetes. 2018 Feb;19(1):14-17. doi: 10.1111/pedi.12535. Epub 2017 Jun 27. No abstract available.

PMID:
28656656
16.

Efficacy and Safety of Mini-Dose Glucagon for Treatment of Nonsevere Hypoglycemia in Adults With Type 1 Diabetes.

Haymond MW, DuBose SN, Rickels MR, Wolpert H, Shah VN, Sherr JL, Weinstock RS, Agarwal S, Verdejo AS, Cummins MJ, Newswanger B, Beck RW; T1D Exchange Mini-dose Glucagon Study Group.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):2994-3001. doi: 10.1210/jc.2017-00591.

PMID:
28591776
17.

Schooling diabetes: Use of continuous glucose monitoring and remote monitors in the home and school settings.

Erie C, Van Name MA, Weyman K, Weinzimer SA, Finnegan J, Sikes K, Tamborlane WV, Sherr JL.

Pediatr Diabetes. 2018 Feb;19(1):92-97. doi: 10.1111/pedi.12518. Epub 2017 Mar 17.

18.

Mitigating Reductions in Glucose During Exercise on Closed-Loop Insulin Delivery: The Ex-Snacks Study.

Patel NS, Van Name MA, Cengiz E, Carria LR, Tichy EM, Weyman K, Weinzimer SA, Tamborlane WV, Sherr JL.

Diabetes Technol Ther. 2016 Dec;18(12):794-799.

19.

No Summer Vacation From Diabetes: Glycemic Control in Pediatric Participants in the T1D Exchange Registry Based on Time of Year.

Sherr JL, Boyle CT, Miller KM, Beck RW, Tamborlane WV; T1D Exchange Clinic Network.

Diabetes Care. 2016 Dec;39(12):e214-e215. Epub 2016 Oct 4. No abstract available.

20.

Response to Comment on Rickels et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care 2016;39:264-270.

Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators.

Diabetes Care. 2016 Oct;39(10):e193-4. doi: 10.2337/dci16-0025. No abstract available.

21.

Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide.

Sherr JL, Patel NS, Michaud CI, Palau-Collazo MM, Van Name MA, Tamborlane WV, Cengiz E, Carria LR, Tichy EM, Weinzimer SA.

Diabetes Care. 2016 Jul;39(7):1127-34. doi: 10.2337/dc16-0089. Epub 2016 May 5.

22.

Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance.

Ly TT, Weinzimer SA, Maahs DM, Sherr JL, Roy A, Grosman B, Cantwell M, Kurtz N, Carria L, Messer L, von Eyben R, Buckingham BA.

Pediatr Diabetes. 2017 Aug;18(5):348-355. doi: 10.1111/pedi.12399. Epub 2016 May 18.

PMID:
27191182
23.

Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes.

Sherr JL, Ruedy KJ, Foster NC, Piché CA, Dulude H, Rickels MR, Tamborlane WV, Bethin KE, DiMeglio LA, Fox LA, Wadwa RP, Schatz DA, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators.

Diabetes Care. 2016 Apr;39(4):555-62. doi: 10.2337/dc15-1606. Epub 2016 Feb 16.

24.

Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.

Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators.

Diabetes Care. 2016 Feb;39(2):264-70. doi: 10.2337/dc15-1498. Epub 2015 Dec 17.

25.

Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries.

Sherr JL, Hermann JM, Campbell F, Foster NC, Hofer SE, Allgrove J, Maahs DM, Kapellen TM, Holman N, Tamborlane WV, Holl RW, Beck RW, Warner JT; T1D Exchange Clinic Network, the DPV Initiative, and the National Paediatric Diabetes Audit and the Royal College of Paediatrics and Child Health registries.

Diabetologia. 2016 Jan;59(1):87-91. doi: 10.1007/s00125-015-3790-6. Epub 2015 Nov 7.

PMID:
26546085
26.

Faster in and faster out: accelerating insulin absorption and action by insulin infusion site warming.

Cengiz E, Weinzimer SA, Sherr JL, Tichy EM, Carria L, Cappiello D, Steffen A, Tamborlane WV.

Diabetes Technol Ther. 2014 Jan;16(1):20-5. doi: 10.1089/dia.2013.0187. Epub 2013 Dec 24.

27.

Safety of nighttime 2-hour suspension of Basal insulin in pump-treated type 1 diabetes even in the absence of low glucose.

Sherr JL, Palau Collazo M, Cengiz E, Michaud C, Carria L, Steffen AT, Weyman K, Zgorski M, Tichy E, Tamborlane WV, Weinzimer SA.

Diabetes Care. 2014;37(3):773-9. doi: 10.2337/dc13-1608. Epub 2013 Oct 29.

28.

Characterization of residual β cell function in long-standing type 1 diabetes.

Sherr JL, Ghazi T, Wurtz A, Rink L, Herold KC.

Diabetes Metab Res Rev. 2014 Feb;30(2):154-62. doi: 10.1002/dmrr.2478.

PMID:
24115337
29.

Diabetes: Insulin pumps in children with T1DM--we told you so.

Tamborlane WV, Sherr JL.

Nat Rev Endocrinol. 2013 Nov;9(11):629-30. doi: 10.1038/nrendo.2013.190. Epub 2013 Oct 1. No abstract available.

PMID:
24080733
30.

Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges.

Ghazi T, Rink L, Sherr JL, Herold KC.

Diabetes Care. 2014;37(1):210-6. doi: 10.2337/dc13-1169. Epub 2013 Aug 12.

31.

Reduced hypoglycemia and increased time in target using closed-loop insulin delivery during nights with or without antecedent afternoon exercise in type 1 diabetes.

Sherr JL, Cengiz E, Palerm CC, Clark B, Kurtz N, Roy A, Carria L, Cantwell M, Tamborlane WV, Weinzimer SA.

Diabetes Care. 2013 Oct;36(10):2909-14. doi: 10.2337/dc13-0010. Epub 2013 Jun 11.

32.

Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device.

Cengiz E, Weinzimer SA, Sherr JL, Tichy E, Martin M, Carria L, Steffen A, Tamborlane WV.

Pediatr Diabetes. 2013 May;14(3):168-73. doi: 10.1111/pedi.12001. Epub 2012 Oct 28.

33.

Effect of insulin feedback on closed-loop glucose control: a crossover study.

Ruiz JL, Sherr JL, Cengiz E, Carria L, Roy A, Voskanyan G, Tamborlane WV, Weinzimer SA.

J Diabetes Sci Technol. 2012 Sep 1;6(5):1123-30.

34.

Clinical equipoise: an argument for expedited approval of the first small step toward an autonomous artificial pancreas.

Cengiz E, Sherr JL, Weinzimer SA, Tamborlane WV.

Expert Rev Med Devices. 2012 Jul;9(4):315-7. doi: 10.1586/erd.12.33. Review. No abstract available.

PMID:
22905835
35.

Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes.

Weinzimer SA, Sherr JL, Cengiz E, Kim G, Ruiz JL, Carria L, Voskanyan G, Roy A, Tamborlane WV.

Diabetes Care. 2012 Oct;35(10):1994-9. Epub 2012 Jul 18.

36.

The alteration of aspart insulin pharmacodynamics when mixed with detemir insulin.

Cengiz E, Swan KL, Tamborlane WV, Sherr JL, Martin M, Weinzimer SA.

Diabetes Care. 2012 Apr;35(4):690-2. doi: 10.2337/dc11-0732. Epub 2012 Feb 28.

37.

Diabetes types 1 and 2 in the pediatric population.

Sherr JL, Weinzimer SA.

Pediatr Ann. 2012 Feb 8;41(2):e1-7. doi: 10.3928/00904481-20120110-09. No abstract available.

PMID:
22299623
38.

New-generation diabetes management: glucose sensor-augmented insulin pump therapy.

Cengiz E, Sherr JL, Weinzimer SA, Tamborlane WV.

Expert Rev Med Devices. 2011 Jul;8(4):449-58. doi: 10.1586/erd.11.22. Review.

39.

A bridge to insulin pump therapy: twice-daily regimen with NPH and detemir insulins during initial treatment of youth with type 1 diabetes mellitus.

Cengiz E, Sherr JL, Erkin-Cakmak A, Weinzimer SA, Burke EN, Sikes KA, Urban AD, Tamborlane WV.

Endocr Pract. 2011 Nov-Dec;17(6):862-6. doi: 10.4158/EP11031.OR.

PMID:
21550949

Supplemental Content

Loading ...
Support Center